ADBICA

ADBICA_structure.png

ADBICA is a synthetic cannabinoid that has been used in scientific research. It is a potent agonist of the cannabinoid receptors, which are part of the endocannabinoid system in the human body. ADBICA is structurally related to other synthetic cannabinoids such as AB-FUBINACA and ADB-PINACA.

Chemical Structure and Properties

ADBICA, also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indole-3-carboxamide, has a complex chemical structure. It belongs to the indole-3-carboxamide family of synthetic cannabinoids. The molecular formula of ADBICA is C22H30N2O2, and it has a molecular weight of 354.49 g/mol.

Pharmacology

ADBICA acts as a full agonist at the CB1 receptor and CB2 receptor, which are the primary receptors in the endocannabinoid system. These receptors are involved in various physiological processes, including pain sensation, mood regulation, and appetite. The binding affinity of ADBICA to these receptors is high, making it a potent synthetic cannabinoid.

Usage and Effects

ADBICA has been used primarily in scientific research to study the effects of synthetic cannabinoids on the human body. It is not approved for medical use and is often found in designer drugs marketed as "legal highs." The effects of ADBICA can include euphoria, relaxation, altered perception, and, in some cases, adverse effects such as anxiety, paranoia, and tachycardia.

Legal Status

The legal status of ADBICA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. For example, in the United States, ADBICA is listed as a Schedule I controlled substance under the Controlled Substances Act.

Safety and Toxicity

The safety profile of ADBICA is not well-established, and its use can be associated with significant health risks. Adverse effects reported in users of synthetic cannabinoids like ADBICA include cardiovascular problems, neurological issues, and psychiatric symptoms. Due to the lack of clinical studies, the long-term effects of ADBICA are unknown.

See Also

• Synthetic cannabinoids
• Endocannabinoid system
• CB1 receptor
• CB2 receptor
• Designer drugs